The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (NATiV3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04849728
Recruitment Status : Recruiting
First Posted : April 19, 2021
Last Update Posted : January 26, 2024
Sponsor:
Information provided by (Responsible Party):
Inventiva Pharma

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

Condition or disease Intervention/treatment Phase
NASH - Nonalcoholic Steatohepatitis Drug: IVA337 Drug: Placebo Phase 3

Detailed Description:

Primary objectives

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage F2 or F3 and consists of 2 sequential parts - an initial double-blind placebo-controlled (DBPC) period (Part A) followed by a double-blind active treatment extension (ATE) period (Part B), with the following primary objectives:

Part A To assess the safety and efficacy of lanifibranor compared to placebo on 'NASH resolution and improvement of fibrosis' assessed by liver histology.

Part B To assess the safety of lanifibranor beyond the DBPC period. Secondary objectives

Key secondary objectives of Part 1:

  • To assess the effect of lanifibranor compared to placebo on NASH resolution and no worsening of fibrosis
  • To assess the effect of lanifibranor compared to placebo on improvement of fibrosis with no worsening of NASH

Other secondary objectives of both Part 1 and Part 2:

  • To assess the effect of lanifibranor on other key histological features of NASH (only for DBPC period)
  • To assess the effect of lanifibranor on NASH resolution and improvement of fibrosis in diabetic patients (only for DBPC period)
  • To assess the effect of lanifibranor on liver tests
  • To assess the effect of lanifibranor on glycaemic parameters
  • To assess the effect of lanifibranor on lipid parameters
  • To assess the effect of lanifibranor on liver stiffness and steatosis assessed by elastography.
  • To assess the effect of lanifibranor on health-related quality of life
  • To assess the safety of lanifibranor
  • To assess population PK modeling through plasma levels of lanifibranor using sparse sampling scheme (only for DBPC period)
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3
Actual Study Start Date : August 19, 2021
Estimated Primary Completion Date : September 30, 2025
Estimated Study Completion Date : September 30, 2026

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Lanifibranor (IVA 337) (800 mg/day)
2 Lanifibranor tablets 400mg + 1 Placebo to match tablet with food --> once a day (quaque die, QD)
 Drug: IVA337
A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
Other Name: Lanifibranor

Drug: Placebo
A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
Experimental: Lanifibranor (IVA 337) (1200 mg/day)
3 Lanifibranor tablets 400mg with food --> once a day (quaque die, QD)
 Drug: IVA337
A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
Other Name: Lanifibranor
Placebo Comparator: Matching placebo
3 Placebo to match tablets with food --> once a day (quaque die, QD)
 Drug: Placebo
A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Resolution of NASH and improvement of fibrosis [ Time Frame: Part A: Date of randomisation until the date of biopsy at Week 72 ]
    Part A: DBPC: Resolution of NASH and improvement of fibrosis at Week 72, defined by NASH CRN scores for ballooning of 0 and inflammation of 0 to 1, and fibrosis score ≥1 stage decrease compared to Baseline

  2. Safety Analyses [ Time Frame: 48 weeks after completion of DBPC period ]

    Part B: ATE:

    • Using the DBPC on-treatment period, comparing the 2 active arms versus placebo
    • Using the DBPC +ATE on treatment periods, assessing the 2 active arms. For adverse events, adjudicated liver events, and DILI and MACE events, in addition to the raw cumulative incidence proportions, the exposure-adjusted incidence rates will be provided based on the time patients are at risk.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Prescreening Criteria:

  • Diagnosed with NASH on prior liver biopsy
  • Type 2 diabetes with high waist circumference or obesity or hepatic steatosis on ultrasound
  • At least 3 of the components of metabolic syndrome

Inclusion Criteria:

  1. Male or female, aged ≥18 years at the time of signing informed consent

  2. Upon central biopsy reading process: diagnosis of NASH according to the Steatosis-Activity-Fibrosis (SAF):

    1. Steatosis score ≥1
    2. Activity score: A3 or A4
    3. Fibrosis score: F2 or F3

  3. No qualitative change in dose for the drugs listed below:

    1. Antidiabetic treatment if glucagon-like peptide-1 receptor agonists (GLP1 receptor agonists) or sodium-glucose co-transporter-2 inhibitors (SGLT2 inhibitors): for at least 3 months
    2. Vitamin E (if at a dose ≥400 IU/day): for at least 6 months
    3. Statins: for at least 3 months
  4. No qualitative change in dose for all other chronically administered drugs for at least 3 months prior to Screening
  5. Weight stable for 6 months prior to Screening and between the qualifying liver biopsy and Baseline (no more than 5% change for both periods)
  6. Negative serum pregnancy test at study Screening for females of childbearing potential confirmed by central laboratory. Females of childbearing potential must practice a consistent and proper use of highly effective method of contraception throughout the study and for 1 month after treatment discontinuation.

Exclusion Criteria:

Liver-related:

  1. Documented causes of chronic liver disease other than NASH
  2. Histologically documented liver cirrhosis (fibrosis stage F4)
  3. History or current diagnosis of hepatocellular carcinoma (HCC)
  4. History of or planned liver transplant
  5. Positive human immunodeficiency virus (HIV) serology
  6. ALT or AST >5 × ULN
  7. AST<0.6 ULN if the liver biopsy has to be performed in the scope of the study
  8. Abnormal synthetic liver function as defined by Screening central laboratory evaluation
  9. Haemoglobin <110 g/L (11 g/dL) for females and <120 g/L (12 g/dL) for males
  10. Patient currently receiving any approved treatment for NASH or obesity
  11. Current or recent history (<5 years) of significant alcohol consumption

  12. Treatment with drugs that may cause non-alcoholic fatty liver disease (NAFLD) administered for at least 2 weeks within 12 months prior to qualifying liver biopsy

    Glycaemia related:

  13. HbA1c >9% at Screening
  14. Diabetes mellitus other than type 2
  15. Current treatment with insulin

  16. Treatment with PPAR-gamma agonists (thiazolidinediones [TZDs]) 12 months before screening or historical biopsy.

    Obesity related:

  17. Bariatric surgery: Restrictive procedures are allowed, if performed >6 months prior to the qualifying liver biopsy; malabsorptive procedures and procedures combining both restrictive and malabsorptive methods are not allowed within 5 years of the qualifying liver biopsy.

    Cardiovascular related:

  18. History of heart failure with reduced left ventricular ejection fraction (LVEF)
  19. Atrial fibrillation requiring anticoagulation
  20. Unstable heart failure

  21. Uncontrolled hypertension at Screening (values >160/100 mm Hg)

    General safety:

  22. Women currently breastfeeding
  23. Previous exposure to lanifibranor
  24. Participation in any clinical trial investigational medicinal product/device within 3 months from Screening or 5 half-lives from Screening, whichever is longer
  25. Concomitant treatment with PPAR-alpha agonists (fibrates)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04849728


Contacts
Layout table for location contacts
Contact: Pascaline Clerc 2024998937/0644637545 clinical.contact@inventivapharma.com

Locations
Show Show 494 study locations
Sponsors and Collaborators
Inventiva Pharma
Investigators
Layout table for investigator information
Principal Investigator: Arun J Sanyal, MD VCU Health, Gastroenterology Hepatology and Nutrition, 1200 West Broad Street, Richmond VA23298, USA
Principal Investigator: Sven Francque, MD Division of Gastroenterology and Hepatology, Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem, Belgium
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Inventiva Pharma
ClinicalTrials.gov Identifier: NCT04849728    
Other Study ID Numbers: 337HNAS20011
First Posted: April 19, 2021    Key Record Dates
Last Update Posted: January 26, 2024
Last Verified: January 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Inventiva Pharma:
Phase III
Nonalcoholic Steatohepatitis
NASH
 Peroxisome proliferator-activated receptor (PPAR)
Liver Diseases
Fibrosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Non-alcoholic Fatty Liver Disease
Fibrosis
 Pathologic Processes
Liver Diseases
Digestive System Diseases